• About us
• Contact

Advertisement

Organisation › Details

AstraZeneca (Group)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. *

 

	Start	1999-04-05 merged
	Industry	pharmaceutical
	Person	Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	1 Francis Crick Avenue Cambridge Biomedical Campus
	City	CB2 0AA Cambridge, Cambridgeshire
		Address record changed: 2024-01-05
Basic data	Employees	I: 50,001 to 100,0 (2022-12-31)
	Currency	USD
	Annual sales	44,351,000,000 (revenue, total, consolidated (2022) 2022-12-31)
	Profit	3,293,000,000 (2022-12-31)
	Cash	6,166,000,000 (2022-12-31)
		* Document for »About Section«: AstraZeneca plc. (11/29/22). "Press Release: AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy".
		Record changed: 2025-03-16

Advertisement

More documents for AstraZeneca (Group)

• [1] AstraZeneca plc. (3/21/25). "Press Release: AstraZeneca to Invest $2.5 Billion in New Global Strategic R&D Centre, Biotech Agreements and Manufacturing in Beijing"....
• [2] AstraZeneca plc. (3/17/25). "Press Release: AstraZeneca Enters License Agreement with Alteogen for Subcutaneous Formulations of Multiple Oncology Assets"....
• [3] FibroGen, Inc.. (2/20/25). "Press Release: FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million". San Francisco, CA....
• [4] EsoBiotec SA. (1/8/24). "Press Release: EsoBiotec Doses First Patient in Investigator Initiated Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma". Mont-Saint-Guibert....
• [5] EsoBiotec SA. (12/11/24). "Press Release: EsoBiotec Begins Clinical Trial of In Vivo BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma". Mont-Saint-Guibert....
• [6] Pinetree Therapeutics, Inc.. (7/23/24). "Press Release: Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca". Cambridge, MA....
• [7] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....
• [8] Allorion Therapeutics Inc.. (1/2/24). "Press Release: Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca". Natick, MA....
• [9] AstraZeneca plc. (12/26/23). "Press Release: AstraZeneca to Acquire Gracell, Furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases"....
• [10] Gracell Biotechnologies Inc.. (12/26/23). "Press Release: Gracell Biotechnologies to Be Acquired by AstraZeneca, furthering Cell Therapy Ambition across Oncology and Autoimmune Diseases". San Diego, CA, Suzhou & Shanghai....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.